HIV Infection
📧 Sign up to get email alerts when something new happens for HIV Infection.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-02-24FDA Approved: ABACAVIR AND LAMIVUDINE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' supplemental application for a generic fixed-dose combination tablet of abacavir and lamivudine for HIV …
-
CLINICAL_TRIALS trial_result · 2020-02-24Clinical Trial Update: Rifaximin for Chronic Immune Activation in People With HIV [Phase 1, Phase 2]
A completed Phase 1/2 trial evaluating rifaximin for chronic immune activation in people with HIV, with results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-02-21Clinical Trial Update: Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults [Phase 1]
Phase 1 trial assessing safety and biological activity of vesatolimod in adults with HIV-1 infection who are virologically suppressed.
-
CLINICAL_TRIALS trial_result · 2020-02-19Clinical Trial Update: DOT Diary Optimization Pilot: A Pilot Study to Optimize the DOT Diary App to Measure PrEP Adherence [Phase 4]
A Phase 4 pilot study evaluated the DOT Diary App to optimize measurement of PrEP adherence and posted results in 2020.
-
CLINICAL_TRIALS trial_result · 2020-02-18Clinical Trial Update: Dosing of Tenofovir and Efavirenz in Antiretroviral Therapy [Phase 4]
Phase 4 trial update on dosing of Tenofovir and Efavirenz in antiretroviral therapy.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-02-18Clinical Trial Update: Optimization of Antiretroviral Therapy [Phase 4]
Phase 4 clinical trial update on optimization of antiretroviral therapy for HIV infections.
-
CLINICAL_TRIALS trial_result · 2020-02-12Clinical Trial Update: Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly [Phase 2]
Phase 2 trial comparing pharmacokinetics and safety of rifabutin 150 mg daily versus 300 mg thrice weekly in HIV and tuberculosis.
-
CLINICAL_TRIALS trial_result · 2020-02-11Clinical Trial Update: The Impact of Omega Three Fatty Acids on Vascular Function in HIV [Phase 4]
Phase 4 trial evaluating the impact of omega-3 fatty acids on vascular function in individuals with HIV and high triglyceride levels; study …
-
FDA approval · 2020-02-10FDA Approved: ZIDOVUDINE — Supplemental Application (Camber Pharmaceuticals, Inc.)
The FDA approved a supplemental application for Zidovudine from Camber Pharmaceuticals, Inc., updating/expanding its approved use or labelin…
-
FDA approval · 2020-02-10FDA Approved: ZIDOVUDINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Zidovudine manufactured by Aurobindo Pharma Limited.
-
FDA approval · 2020-02-07FDA Approved: DRONABINOL — Original Application (Camber Pharmaceuticals Inc)
FDA approves Camber Pharmaceuticals' original abbreviated new drug application for dronabinol (generic). The product is indicated for chemot…
-
CLINICAL_TRIALS trial_result · 2020-02-05Clinical Trial Update: A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study [Phase 4]
Phase IV, open-label pilot trial assessing potential neurotoxicity of Dolutegravir/Lamivudine/Abacavir and reversibility after switching to …
-
CLINICAL_TRIALS trial_result · 2020-02-05Clinical Trial Update: Botswana TDF/FTC Oral HIV Prophylaxis Trial [Phase 2, Phase 3]
Clinical trials in Botswana evaluated TDF/FTC as oral HIV prophylaxis in Phase 2 and Phase 3; status completed with results posted in 2020.
-
FDA approval · 2020-02-04FDA Approved: EFAVIRENZ — Supplemental Application (Aurobindo Pharma Limited)
FDA granted approval of a supplemental application for efavirenz from Aurobindo Pharma Limited, authorizing its continued generic use and po…
-
FDA approval · 2020-02-04FDA Approved: EFAVIRENZ — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Efavirenz by Aurobindo Pharma Limited, updating the product’s approval status for the treatment …
-
CLINICAL_TRIALS trial_result · 2020-01-31Clinical Trial Update: Efficacy of Treatment Intensification With Maraviroc on HIV-1 Viral Latency in Recently Infected Hiv-1 naïve Patients Starting Raltegravir Plus Tenofovir/Emtricitabine [Phase 3]
Phase 3 trial evaluating whether intensifying HIV therapy with maraviroc improves viral latency outcomes in recently infected, ART-naïve pat…
-
CLINICAL_TRIALS trial_result · 2020-01-31Clinical Trial Update: Switching From Protease Inhibitor (PI) to Etravirine in HIV-1 Infected Subjects With Viremia Suppression [Phase 3]
Clinical trial update evaluating switching from protease inhibitor to etravirine in HIV-1 infected subjects with suppressed viremia (Phase 3…
-
CLINICAL_TRIALS trial_result · 2020-01-31Clinical Trial Update: Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen [Phase 3]
Phase 3 trial updating neurological monitoring for patients switching from dolutegravir to bictegravir-based regimens.
-
CLINICAL_TRIALS trial_result · 2020-01-30Clinical Trial Update: Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine [Phase 2]
Phase 2 dose-ranging trial evaluating GSK1265744 with NRTIs for induction and maintenance of HIV-1 virologic suppression; study completed wi…
-
CLINICAL_TRIALS trial_result · 2020-01-29Clinical Trial Update: Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4 [Phase 2]
Phase 2 trial evaluating short-duration therapy for acute hepatitis C genotypes 1 or 4; results posted after completion.
-
CLINICAL_TRIALS trial_result · 2020-01-28Clinical Trial Update: Repeated DermaVir Immunizations in HIV-1 Infected Treatment-naïve Patients [Phase 2]
Phase 2 clinical trial update on repeated DermaVir immunizations in treatment-naïve HIV-1 infected patients has completed.
-
CLINICAL_TRIALS trial_result · 2020-01-28Clinical Trial Update: Switching From Tenofovir Disoproxil Fumarate to Abacavir or Tenofovir Alafenamide [Phase 4]
Phase 4 trial update evaluating switching from tenofovir disoproxil fumarate to abacavir or tenofovir alafenamide in individuals with chroni…
-
FDA approval · 2020-01-27FDA Approved: EFAVIRENZ, EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for a generic fixed-dose combination of efavirenz, emtricitabine, and tenofovir disoproxil fumarate …
-
CLINICAL_TRIALS trial_result · 2020-01-27Clinical Trial Update: Effects of Docosahexanoic Acid on Neurocognitive Impairment in HIV-infected Patients [Phase 1, Phase 2]
Clinical trial update on docosahexaenoic acid (DHA) for neurocognitive impairment in HIV-infected patients (Phase 1/Phase 2).
-
FDA approval · 2020-01-23FDA Approved: TENOFOVIR DISOPROXIL FUMARATE — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved a supplemental application for Camber Pharmaceuticals’ generic tenofovir disoproxil fumarate.